|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2000-6-7
|
|
pubmed:abstractText |
9-Amino-20(S)-camptothecin (9-AC) is a specific inhibitor of topoisomerase-I. Recently, a bioavailability of approximately 48% for the oral PEG-1000 formulation was reported. We conducted a phase I and pharmacokinetic study of the oral PEG-1000 formulation of 9-AC to define the maximum-tolerated dose, toxicity profiles, pharmacokinetic-dynamic relationships, and preliminary antitumor activity in patients with solid tumors.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
pubmed-author:DallaireB KBK,
pubmed-author:GelderblomA HAH,
pubmed-author:LoosW JWJ,
pubmed-author:PlantingA SAS,
pubmed-author:RiesCC,
pubmed-author:SparreboomAA,
pubmed-author:VerweijJJ,
pubmed-author:WagenerD JDJ,
pubmed-author:de JongeM JMJ,
pubmed-author:van BeurdenVV,
pubmed-author:van MaanenL WLW,
pubmed-author:van der BurgM EME
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
17
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2219-26
|
|
pubmed:dateRevised |
2004-11-17
|
|
pubmed:meshHeading |
pubmed-meshheading:10561279-Administration, Oral,
pubmed-meshheading:10561279-Adult,
pubmed-meshheading:10561279-Aged,
pubmed-meshheading:10561279-Antineoplastic Agents,
pubmed-meshheading:10561279-Camptothecin,
pubmed-meshheading:10561279-Dose-Response Relationship, Drug,
pubmed-meshheading:10561279-Female,
pubmed-meshheading:10561279-Humans,
pubmed-meshheading:10561279-Least-Squares Analysis,
pubmed-meshheading:10561279-Likelihood Functions,
pubmed-meshheading:10561279-Male,
pubmed-meshheading:10561279-Middle Aged,
pubmed-meshheading:10561279-Neoplasms,
pubmed-meshheading:10561279-Neutropenia,
pubmed-meshheading:10561279-Pharmacokinetics,
pubmed-meshheading:10561279-Thrombocytopenia
|
|
pubmed:year |
1999
|
|
pubmed:articleTitle |
Phase I and pharmacologic study of oral (PEG-1000) 9-aminocamptothecin in adult patients with solid tumors.
|
|
pubmed:affiliation |
Department of Medical Oncology, Rotterdam Cancer Institute (Daniel den Hoed Kliniek) and University Hospital, Rotterdam, The Netherlands. jonge@onch.azr.nl
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase I
|
